Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation?
- PMID: 34101538
- PMCID: PMC8437539
- DOI: 10.1080/21645515.2021.1924521
Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation?
Abstract
Classical Hodgkin lymphoma is a neoplastic hematological disease. Standard first-line therapy, including chemotherapy and radiotherapy, is curative in >85% of early-stage patients, with a 5-year survival rate of >95%. However, approximately 15% of patients have hard-to-treat lymphoma with poor outcomes, and new treatment strategies are needed for these young adults. There are several well-documented cases in the medical literature on hematologic cancer remission following natural human viral infections. Therefore, hoping to reproduce these spontaneous tumor regressions, researchers have been investigating various viruses with oncolytic properties. There is a high rationale for using virotherapy in the treatment of Hodgkin lymphoma, in which tumor cells are often infected with the Epstein-Barr virus. Modern viral technologies and current knowledge about the relationship between viruses and cancer could accelerate the discovery of effective viral oncolytic therapies. This article reviews the use of oncolytic viruses as innovative therapies for treating Hodgkin lymphoma.
Keywords: Epstein-Barr virus; Hodgkin lymphoma; oncolytic viruses; virotherapy.
Figures
Similar articles
-
Oncolytic viruses as emerging therapy against cancers including Oncovirus-induced cancers.Eur J Pharmacol. 2023 Jan 15;939:175393. doi: 10.1016/j.ejphar.2022.175393. Epub 2022 Nov 23. Eur J Pharmacol. 2023. PMID: 36435236
-
[Expression of ZEBRA protein of Epstein-Barr virus in Hungarian patients with Hodgkin lymphoma: latent or lytic cycle?].Orv Hetil. 2006 Aug 20;147(33):1539-44. Orv Hetil. 2006. PMID: 17037676 Hungarian.
-
Lymphomas and oncolytic virus therapy.Clin Lymphoma. 2003 Sep;4(2):104-11. doi: 10.3816/clm.2003.n.019. Clin Lymphoma. 2003. PMID: 14556682 Review.
-
Longer failure-free survival interval of Epstein-Barr virus-associated classical Hodgkin's lymphoma: a single-institution study.Mod Pathol. 2003 Jun;16(6):566-73. doi: 10.1097/01.MP.0000071843.09960.BF. Mod Pathol. 2003. PMID: 12808062
-
Oncolytic viruses as a promising therapeutic strategy for hematological malignancies.Biomed Pharmacother. 2021 Jul;139:111573. doi: 10.1016/j.biopha.2021.111573. Epub 2021 Apr 22. Biomed Pharmacother. 2021. PMID: 33894623 Review.
References
-
- Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th rev ed. IARC; 2017. Sep 18.
-
- Anagnostopoulos I, Hansmann M-L, Franssila K, Harris M, Harris NL, Jaffe ES, Han J, Van Krieken JM, Poppema S, Marafioti T, et al. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood. 2000;96(5):1889–99. doi:10.1182/blood.V96.5.1889. - DOI - PubMed
-
- Lanzkowsky’s manual of pediatric hematology and oncology. 6th ed. [accessed 2021. Mar 13]. https://www.elsevier.com/books/lanzkowskys-manual-of-pediatric-hematolog....
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical